Cargando…
2778. Retrospective evaluation of effectiveness of Flomoxef for infections due to extended-spectrum β-lactamase-producing Enterobacterales
BACKGROUND: Flomoxef (FMOX), an oxacephem, is resistant to hydrolysis by extended-spectrum β-lactamase (ESBL), and is expected to serve as a carbapenem-sparing therapy for infections caused by ESBL-producing Enterobacterales (ESBLPE). FMOX has been approved and used in Japan for the treatment of ESB...
Autores principales: | Koizumi, Ryuji, Hayakawa, Kayoko, Hamada, Yukihiro, Mezaki, Kazuhisa, Ohmagari, Norio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677099/ http://dx.doi.org/10.1093/ofid/ofad500.2389 |
Ejemplares similares
-
Pharmacokinetic/Pharmacodynamic Analysis and Dose Optimization of Cefmetazole and Flomoxef against Extended-Spectrum β-Lactamase-Producing Enterobacterales in Patients with Invasive Urinary Tract Infection Considering Renal Function
por: Hamada, Yukihiro, et al.
Publicado: (2022) -
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2021) -
Correction to: Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales
por: Darlow, Christopher A, et al.
Publicado: (2022) -
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales—authors’ response
por: Darlow, Christopher A, et al.
Publicado: (2022) -
In vitro efficacy of humanized regimen of flomoxef against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae
por: Yamashiro, Hidenori, et al.
Publicado: (2023)